Nasopharyngeal airway plus high-flow nasal oxygen during painless gastroscopy for people with obesity

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study enrolls adults with BMI over 28 who are scheduled for sedated (painless) gastroscopy and are ASA physical status I–III. Participants receive a nasopharyngeal airway combined with high-flow nasal oxygen during the procedure, and clinicians monitor oxygen saturation and respiratory events. The main goal is to reduce the incidence of hypoxia and related airway complications during sedated endoscopy in obese patients. The trial is conducted at Nanjing First Hospital as a single-center protocol with periprocedural monitoring and follow-up.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients undergoing painless gastroscopy;
2. Patients with an age greater than 18 years old;
3. American Society of Anesthesiologists (ASA) physical status classification from Grade I to Grade III;
4. Body Mass Index (BMI) greater than 28 kg/m²

Exclusion Criteria:

1. Patients with contraindications to endoscopic procedures or those who refuse sedation/anesthesia;
2. Patients allergic to propofol, eggs, soybeans, milk, etc.;
3. Patients with gastrointestinal tract obstruction and gastric emptying disorders;
4. Patients with acute pharyngitis, tonsillitis, and upper respiratory tract infections;
5. Patients in the acute exacerbation stage of respiratory diseases such as asthma, bronchitis, and chronic obstructive pulmonary disease (COPD);
6. Patients with acute arrhythmia and those with severe heart diseases (congenital diseases, valvular diseases);
7. Patients with severe hepatic and renal insufficiency who require alternative treatment;
8. Patients with severe mental disorders who need medications to control their symptoms;
9. Patients with moderate or above anemia, abnormal coagulation function, and hematological diseases;
10. Patients with nasal cavity lesions leading to severe nasal congestion;
11. Pregnant and lactating patients.

Where it's running

• Nanjing First Hospital
  Nanjing, China Recruiting

Study contacts

• Study coordinator: Jing Hu, Master
• Email: hujingmz@163.com
• Phone: 15366110201

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.